Pharma stocks had a mixed response after Finance Minister Nirmala Sitharaman announced customs duty exemptions for 36 ...

The Nifty Pharma index fell nearly 3% in intraday trade on January 28, marking its third consecutive session of decline, with ...

Finance Minister Sitharaman announced the inclusion of six life-saving drugs in the concessional 5% duty slab to enhance ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...

Rivals Sun Pharma and Cipla beat third-quarter profit estimates, while Dr Reddy's missed expectations. All three drugmakers ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

The US healthcare system under Trump 2.0 are likely to benefit Indian players, except for the push for increased US drug ...

Indian drugmaker Alembic Pharmaceuticals reported a lower third-quarter profit on Monday, weighed down by weak local sales of its drugs that treat acute illnesses.

A significant chunk of revenue for most Indian generic drugmaker comes from the U.S. and fierce competition in the North ...

Indian pharmaceutical companies lag behind global peers in ESG practices, facing regulatory, awareness, and resource ...

India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

Sun Pharmaceutical , India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided ...